1
|
Tsonkova VG, Sand FW, Wolf XA, Grunnet LG, Kirstine Ringgaard A, Ingvorsen C, Winkel L, Kalisz M, Dalgaard K, Bruun C, Fels JJ, Helgstrand C, Hastrup S, Öberg FK, Vernet E, Sandrini MPB, Shaw AC, Jessen C, Grønborg M, Hald J, Willenbrock H, Madsen D, Wernersson R, Hansson L, Jensen JN, Plesner A, Alanentalo T, Petersen MBK, Grapin-Botton A, Honoré C, Ahnfelt-Rønne J, Hecksher-Sørensen J, Ravassard P, Madsen OD, Rescan C, Frogne T. The EndoC-βH1 cell line is a valid model of human beta cells and applicable for screenings to identify novel drug target candidates. Mol Metab 2018; 8:144-157. [PMID: 29307512 PMCID: PMC5985049 DOI: 10.1016/j.molmet.2017.12.007] [Citation(s) in RCA: 85] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/12/2017] [Accepted: 12/13/2017] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE To characterize the EndoC-βH1 cell line as a model for human beta cells and evaluate its beta cell functionality, focusing on insulin secretion, proliferation, apoptosis and ER stress, with the objective to assess its potential as a screening platform for identification of novel anti-diabetic drug candidates. METHODS EndoC-βH1 was transplanted into mice for validation of in vivo functionality. Insulin secretion was evaluated in cells cultured as monolayer and as pseudoislets, as well as in diabetic mice. Cytokine induced apoptosis, glucolipotoxicity, and ER stress responses were assessed. Beta cell relevant mRNA and protein expression were investigated by qPCR and antibody staining. Hundreds of proteins or peptides were tested for their effect on insulin secretion and proliferation. RESULTS Transplantation of EndoC-βH1 cells restored normoglycemia in streptozotocin induced diabetic mice. Both in vitro and in vivo, we observed a clear insulin response to glucose, and, in vitro, we found a significant increase in insulin secretion from EndoC-βH1 pseudoislets compared to monolayer cultures for both glucose and incretins. Apoptosis and ER stress were inducible in the cells and caspase 3/7 activity was elevated in response to cytokines, but not affected by the saturated fatty acid palmitate. By screening of various proteins and peptides, we found Bombesin (BB) receptor agonists and Pituitary Adenylate Cyclase-Activating Polypeptides (PACAP) to significantly induce insulin secretion and the proteins SerpinA6, STC1, and APOH to significantly stimulate proliferation. ER stress was readily induced by Tunicamycin and resulted in a reduction of insulin mRNA. Somatostatin (SST) was found to be expressed by 1% of the cells and manipulation of the SST receptors was found to significantly affect insulin secretion. CONCLUSIONS Overall, the EndoC-βH1 cells strongly resemble human islet beta cells in terms of glucose and incretin stimulated insulin secretion capabilities. The cell line has an active cytokine induced caspase 3/7 apoptotic pathway and is responsive to ER stress initiation factors. The cells' ability to proliferate can be further increased by already known compounds as well as by novel peptides and proteins. Based on its robust performance during the functionality assessment assays, the EndoC-βH1 cell line was successfully used as a screening platform for identification of novel anti-diabetic drug candidates.
Collapse
Affiliation(s)
- Violeta Georgieva Tsonkova
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, Department of Biomedical Sciences, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark
| | - Fredrik Wolfhagen Sand
- Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Xenia Asbæk Wolf
- Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Lars Groth Grunnet
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Anna Kirstine Ringgaard
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, Department of Biomedical Sciences, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark
| | - Camilla Ingvorsen
- Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Louise Winkel
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Mark Kalisz
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Kevin Dalgaard
- Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Christine Bruun
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Johannes Josef Fels
- Novo Nordisk A/S, Discovery Biology & Technology, Research Bioanalysis, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Charlotte Helgstrand
- Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Sven Hastrup
- Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Fredrik Kryh Öberg
- Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Erik Vernet
- Novo Nordisk Research Center Seattle Inc., Protein Engineering, NNRC Seattle, Inc., 530 Fairview Avenue North, 98109, Seattle, WA, USA
| | | | - Allan Christian Shaw
- Novo Nordisk A/S, Protein Engineering, Characterisation & Modelling Technology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Carsten Jessen
- Novo Nordisk A/S, Protein Engineering, Protein & Peptide Chemistry 2, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Mads Grønborg
- Novo Nordisk A/S, Discovery Biology & Technology, Discovery ADME, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Jacob Hald
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Hanni Willenbrock
- Novo Nordisk A/S, Discovery Biology & Technology, Bioinformatics, Maaloev, Denmark
| | - Dennis Madsen
- Novo Nordisk A/S, Discovery Biology & Technology, Bioinformatics, Maaloev, Denmark
| | | | - Lena Hansson
- Intomics A/S, Lottenborgvej 26, DK-2800, Lyngby, Denmark; Novo Nordisk Pharma Ltd., Research Centre Oxford, Bioinformatics, Novo Nordisk Ltd., 3 City Place Beehive Ring Road, Gatwick, RH6 0PA, West Sussex, United Kingdom
| | - Jan Nygaard Jensen
- Novo Nordisk Pharma Ltd., Research Centre Oxford, Bioinformatics, Novo Nordisk Ltd., 3 City Place Beehive Ring Road, Gatwick, RH6 0PA, West Sussex, United Kingdom
| | - Annette Plesner
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Tomas Alanentalo
- Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Maja Borup Kjær Petersen
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, DanStem, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark
| | - Anne Grapin-Botton
- University of Copenhagen, DanStem, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark
| | - Christian Honoré
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Jonas Ahnfelt-Rønne
- Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Jacob Hecksher-Sørensen
- Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Philippe Ravassard
- Institut du cerveau et de la moelle (ICM) - Hôpital Pitié-Salpêtrière, Boulevard de l'Hôpital, Sorbonne Universités, Inserm, CNRS, UPMC Univ, Paris 06, Paris, France
| | - Ole D Madsen
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Claude Rescan
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark
| | - Thomas Frogne
- Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
| |
Collapse
|
2
|
Abstract
This review article has for major main objectives to give an overlook of the major physiological effects of somatostatin on different organs. It will cover first the general aspect of the hormone, its cDNA and its protein maturation process, as well as its characterization in various organs. This aspect will be followed by the factors involved in the control of its secretion, its intracellular mode of action, and its general action on physiological processes. Secondly, the review will focus on the pancreas, looking at its in vivo and in vitro actions with special attention on its effects on normal pancreas growth and pancreatic tumors.
Collapse
Affiliation(s)
- Jean Morisset
- From the Département de Médecine, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec, Canada
| |
Collapse
|
3
|
Pierre JF, Neuman JC, Brill AL, Brar HK, Thompson MF, Cadena MT, Connors KM, Busch RA, Heneghan AF, Cham CM, Jones EK, Kibbe CR, Davis DB, Groblewski GE, Kudsk KA, Kimple ME. The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition. Am J Physiol Gastrointest Liver Physiol 2015; 309:G431-42. [PMID: 26185331 PMCID: PMC4572409 DOI: 10.1152/ajpgi.00072.2015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 07/02/2015] [Indexed: 01/31/2023]
Abstract
Stimulation of digestive organs by enteric peptides is lost during total parental nutrition (PN). Here we examine the role of the enteric peptide bombesin (BBS) in stimulation of the exocrine and endocrine pancreas during PN. BBS protects against exocrine pancreas atrophy and dysfunction caused by PN. BBS also augments circulating insulin levels, suggesting an endocrine pancreas phenotype. While no significant changes in gross endocrine pancreas morphology were observed, pancreatic islets isolated from BBS-treated PN mice showed a significantly enhanced insulin secretion response to the glucagon-like peptide-1 (GLP-1) agonist exendin-4, correlating with enhanced GLP-1 receptor expression. BBS itself had no effect on islet function, as reflected in low expression of BBS receptors in islet samples. Intestinal BBS receptor expression was enhanced in PN with BBS, and circulating active GLP-1 levels were significantly enhanced in BBS-treated PN mice. We hypothesized that BBS preserved islet function indirectly, through the enteroendocrine cell-pancreas axis. We confirmed the ability of BBS to directly stimulate intestinal enteroid cells to express the GLP-1 precursor preproglucagon. In conclusion, BBS preserves the exocrine and endocrine pancreas functions during PN; however, the endocrine stimulation is likely indirect, through the enteroendocrine cell-pancreas axis.
Collapse
Affiliation(s)
- Joseph F. Pierre
- 2Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin; ,5Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Joshua C. Neuman
- 4Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison College of Agriculture and Life Sciences, Madison, Wisconsin; and
| | - Allison L. Brill
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Harpreet K. Brar
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Mary F. Thompson
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Mark T. Cadena
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Kelsey M. Connors
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Rebecca A. Busch
- 2Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Aaron F. Heneghan
- 2Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Candace M. Cham
- 5Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Elaina K. Jones
- 4Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison College of Agriculture and Life Sciences, Madison, Wisconsin; and
| | - Carly R. Kibbe
- 3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Dawn B. Davis
- 1William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin; ,3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin; ,4Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison College of Agriculture and Life Sciences, Madison, Wisconsin; and
| | - Guy E. Groblewski
- 4Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison College of Agriculture and Life Sciences, Madison, Wisconsin; and
| | - Kenneth A. Kudsk
- 1William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin; ,2Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin;
| | - Michelle E. Kimple
- 1William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin; ,3Division of Endocrinology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin; ,4Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison College of Agriculture and Life Sciences, Madison, Wisconsin; and
| |
Collapse
|
4
|
Marenah L, Flatt PR, Orr DF, McClean S, Shaw C, Abdel-Wahab YHA. Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures. Biol Chem 2004; 385:315-21. [PMID: 15134346 DOI: 10.1515/bc.2004.027] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Skin secretions of the toad Bombina variegata were evaluated for the isolation and characterisation of insulinotropic peptides. Crude secretions obtained from young adult toads by mild electrical stimulation of the dorsal skin surface were purified by reverse phase HPLC yielding 44 peaks. In acute incubations with glucose-responsive BRIN-BD11 cells, peaks 21, 22, 23, 24 and 25 showed a 1.5-3.5-fold increase in insulin release compared with 5.6 mM glucose alone (p<0.001; n=3). Structural analyses of the purified insulin-releasing peaks were performed by automated Edman degradation and mass spectrometry. Peptides represented by peaks 21, 22 and 23 had molecular masses of 1641.7 Da, 1662.6 Da and 1619.8 Da respectively. These peptides were unblocked by removal of pyroglutamic acid from the N-terminus prior to Edman degradation, revealing lengths of 14 amino acids. Peak 21 yielded a primary structure of Pyr-QRLGHQWAVGHLM, which a data base search revealed as an analogue of bombesin (His6 bombesin), while peak 23 was an exact match of bombesin (Pyr-QRLGNQWAVGHLM) originally isolated from Bombina bombina. Peak 22 indicated a primary structure of Pyr-DSFGNQWARGHFM (72% homology with bombesin). Peaks 24 and 25 revealed entirely novel insulinotropic peptides with molecular masses and primary structures of 1650.5 Da and 2300.0 Da and GKPFYPPPIYPEDM (GM-14) and IYNAICPCKHCNKCKPGLLAN (IN-21) respectively. Preliminary studies on the mechanisms underlying the insulinotropic actions of peaks 21, 22, 23 and 24 suggest possible involvement of a cAMP-dependent, G protein-insensitive pathway. These data indicate that Bombina variegata skin secretions contain peptides with insulin-releasing activity, which may have mammalian counterparts and prove useful for possible exploitation as antidiabetic agents from natural resources.
Collapse
Affiliation(s)
- Lamin Marenah
- School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, N. Ireland, BT52 1SA, UK.
| | | | | | | | | | | |
Collapse
|
5
|
Mollet A, Meier S, Grabler V, Gilg S, Scharrer E, Lutz TA. Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. Peptides 2003; 24:91-8. [PMID: 12576089 DOI: 10.1016/s0196-9781(02)00280-2] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Previous studies indicated that amylin contributes to the anorectic effects of cholecystokinin (CCK) and bombesin (BBS), possibly by enhancing the release of pancreatic amylin or by modulating their anorectic actions within the central nervous system (CNS). To elucidate the interaction between amylin and CCK or BBS, respectively, we investigated the influence of an IP injection of CCK or BBS on feeding in amylin-deficient mice (IAPP(-/-)). The anorectic effects of CCK and BBS were nearly abolished in IAPP(-/-) mice compared to wildtype (WT) mice (e.g. 20 microg/kg CCK, 1-h food intake: WT/NaCl 0.53 +/- 0.03 g; WT/CCK 0.16 +/- 0.03 g (P < 0.001); IAPP(-/-)/NaCl 0.49 +/- 0.05 g; IAPP(-/-)/CCK 0.39 +/- 0.04 g). Acute amylin replacement restored the anorectic effect of CCK in IAPP(-/-) mice. To find out whether CCK or BBS enhance the feeding-induced release of pancreatic amylin, we injected rats with CCK-8 (0.5-50 microg/kg) or BBS (5 microg/kg) and measured plasma amylin levels after injections. Neither CCK nor BBS increased the plasma amylin level in rats. We suggest that the mediation of the anorectic effects of CCK and BBS by amylin is not dependent on a CCK- or BBS-induced release of pancreatic amylin, but may rather be due to a modulation of their effects by amylin within the CNS.
Collapse
Affiliation(s)
- A Mollet
- Institute of Veterinary Physiology, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland
| | | | | | | | | | | |
Collapse
|
6
|
Schöfl C, Börger J, Mader T, Waring M, von zur Mühlen A, Brabant G. Tolbutamide and diazoxide modulate phospholipase C-linked Ca(2+) signaling and insulin secretion in beta-cells. Am J Physiol Endocrinol Metab 2000; 278:E639-47. [PMID: 10751197 DOI: 10.1152/ajpendo.2000.278.4.e639] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Arginine vasopressin (AVP), bombesin, and ACh increase cytosolic free Ca(2+) and potentiate glucose-induced insulin release by activating receptors linked to phospholipase C (PLC). We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PLC-linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PLC-linked insulin secretion from HIT-T15 cells. In the presence of glucose, the PLC-linked Ca(2+) signals were enhanced by tolbutamide (3-300 microM) and inhibited by diazoxide (10-100 microM). The effects of tolbutamide and diazoxide on PLC-linked Ca(2+) signaling were mimicked by BAY K 8644 and nifedipine, an activator and inhibitor of L-type voltage-sensitive Ca(2+) channels, respectively. Neither tolbutamide nor diazoxide affected PLC-linked mobilization of internal Ca(2+) or store-operated Ca(2+) influx through non-L-type Ca(2+) channels. In the absence of glucose, PLC-linked Ca(2+) signals were diminished or abolished; this effect could be partly antagonized by tolbutamide. In the presence of glucose, tolbutamide potentiated and diazoxide inhibited AVP- or bombesin-induced insulin secretion from HIT-T15 cells. Nifedipine (10 microM) blocked both the potentiating and inhibitory actions of tolbutamide and diazoxide on AVP-induced insulin release, respectively. In glucose-free medium, AVP-induced insulin release was reduced but was again potentiated by tolbutamide, whereas diazoxide caused no further inhibition. Thus tolbutamide and diazoxide regulate both PLC-linked Ca(2+) signaling and insulin secretion from pancreatic beta-cells by modulating K(ATP) channels, thereby determining voltage-sensitive Ca(2+) influx.
Collapse
Affiliation(s)
- C Schöfl
- Abteilung Klinische Endokrinologie, Medizinische Hochschule Hannover, 30623 Hannover, Germany.
| | | | | | | | | | | |
Collapse
|
7
|
Lutz TA, Pieber TR, Walzer B, Del Prete E, Scharrer E. Different influence of CGRP (8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats. Peptides 1997; 18:643-9. [PMID: 9213356 DOI: 10.1016/s0196-9781(97)00124-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Because previous studies had suggested that the anorectic effects of cholecystokinin (CCK) and bombesin (BBS) depend partly on the release of amylin or calcitonin gene-related peptide (CGRP), we investigated the influence of the amylin and CGRP receptor antagonist CGRP (8-37) on the anorectic effects of CCK and BBS in streptozotocin (STZ)-diabetic and nondiabetic rats. STZ-diabetic rats had significantly lower plasma amylin and insulin concentrations than nondiabetic control rats. Amylin (5 micrograms/kg or 2.5 micrograms/rat) injected IP at dark onset after 24-h food deprivation elicited an anorectic effect of similar extent in STZ-diabetic and control rats. Under similar conditions, CCK (0.25 and 2 micrograms/kg) and BBS (5 micrograms/kg) reduced food intake in both STZ-diabetic and nondiabetic rats. These effects were markedly attenuated by CGRP (8-37) (10 micrograms/kg) in non-diabetics but not in STZ-diabetic rats. It is concluded that part of the anorectic effects of CCK and BBS depend on the release of amylin from pancreatic B-cells.
Collapse
Affiliation(s)
- T A Lutz
- Institute of Veterinary Physiology, University of Zuerich, Switzerland
| | | | | | | | | |
Collapse
|
8
|
Schöfl C, Rössig L, Leitolf H, Mader T, von zur Mühlen A, Brabant G. Generation of repetitive Ca2+ transients by bombesin requires intracellular release and influx of Ca2+ through voltage-dependent and voltage independent channels in single HIT cells. Cell Calcium 1996; 19:485-93. [PMID: 8842515 DOI: 10.1016/s0143-4160(96)90057-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In the present study, the bombesin-induced changes in cytosolic free Ca2+ ([Ca2+]i) were investigated in single Fura-2 loaded SV-40 transformed hamster beta-cells (HIT). Bombesin (50-500 pM) caused frequency-modulated repetitive Ca2+ transients. The average frequency of the Ca2+ transients induced by bombesin (200 pM) was 0.58 +/- 0.02 min-1 (n = 121 cells). High concentrations of bombesin (> or = 2 nM) triggered a large initial Ca2+ transient followed by a sustained plateau or by a decrease to basal levels. In Ca(2+)- free medium, bombesin caused only one or two Ca2+ transients and withdrawal of extracellular Ca2+ abolished the Ca2+ transients. The voltage-dependent Ca2+ channel (VDCC) blockers, verapamil (50 microM) and nifedipine (10 microM), reduced amplitude and frequency of the Ca2+ transients and stopped the Ca2+ transients in some cells. Thapsigargin caused a sustained rise in [Ca2+]i in the presence of extracellular Ca2+ while in its absence the rise in [Ca2+]i was transient. Verapamil (50 microM) inhibited the thapsigargin-induced increase in [Ca2+]i by about 50%. Depletion of intracellular Ca2+ stores by repetitive stimulation with increasing concentrations of bombesin or thapsigargin in Ca(2+)-free medium caused an agonist-independent increase in [Ca2+]i when extracellular Ca2+ was restored, which was larger than in control cells that had been incubated in Ca(2+)-free medium for the same period of time. This rise in [Ca2+]i and the thapsigargin-induced increase in [Ca2+]i were only partly inhibited by VDCC-blockers. Thus, depletion of the agonist-sensitive Ca2+ pool enhances Ca2+ influx through VDCC and voltage-independent Ca2+ channels (VICC). In conclusion, the bombesin-induced Ca2+ response in single HIT cells is periodic in nature with frequency-modulated repetitive Ca2+ transients. Intracellular Ca2+ is mobilized during each Ca2+ transient, but Ca2+ influx through VDCC and VICC is required for maintaining the sustained nature of the Ca2+ response. Ca2+ influx in whole or part is activated by a capacitative Ca2+ entry mechanism.
Collapse
Affiliation(s)
- C Schöfl
- Abteilung Klinische Endokrinologie, Medizinische Hochschule Hannover, Germany
| | | | | | | | | | | |
Collapse
|
9
|
Ammon HP. [Routes to normalization in the stimulation of insulin secretion]. PHARMAZIE IN UNSERER ZEIT 1996; 25:123-9. [PMID: 8768052 DOI: 10.1002/pauz.19960250306] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- H P Ammon
- Lehrstuhl Pharmakologie für Naturwissenschaftler, Pharmazeutisches Institut der Universität Tübingen
| |
Collapse
|
10
|
Lutz TA, Del Prete E, Szabady MM, Scharrer E. Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP(8-37). Peptides 1996; 17:119-24. [PMID: 8822520 DOI: 10.1016/0196-9781(95)02046-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The anorectic effect of IP injection of amylin (1 microgram/kg) was abolished by simultaneous IP injection of the amylin receptor antagonist calcitonin gene-related peptide-(8-37) [CGRP(8-37), 10 micrograms/kg]. The IP injection of pancreatic glucagon (400 micrograms/kg) at dark onset also reduced food intake in 24-h food-deprived rats, and this effect was also totally blocked by coadministration of CGRP(8-37) (10 micrograms/kg). In another feeding paradigm with glucagon (540 micrograms/kg IP 3 h into the light phase in 3 h-prefed rats), however, the anorectic effect of glucagon was not significantly antagonized by CGRP(8-37). The anorectic effect of cholecystokinin (CCK) (0.25 microgram/kg) and bombesin (BBS) (2 micrograms/kg) was partly neutralized by CGRP(8-37). In contrast, the anorectic effect of vasopressin (VP) (2.5 micrograms/kg) was not influenced by CGRP(8-37). As glucagon has been shown previously to increase the secretion of amylin, we conclude that the anorectic effect of peripherally administered glucagon is mediated by the release of amylin, at least under certain conditions. This may also be true for CCK and BBS, as these peptides are insulinotropic and may therefore be presumed to increase amylin release.
Collapse
Affiliation(s)
- T A Lutz
- Institute of Veterinary Physiology, University of Zuerich, Switzerland
| | | | | | | |
Collapse
|
11
|
Walsh JH. Bombesin‐like Peptides. Compr Physiol 1989. [DOI: 10.1002/cphy.cp060224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
McDonald TJ, Houghton P, Challis JR, Hramiak IM. The effect of gastrin-releasing peptide on the endocrine pancreas. Ann N Y Acad Sci 1988; 547:242-54. [PMID: 3071222 DOI: 10.1111/j.1749-6632.1988.tb23893.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Infusion of GRP into conscious sheep and dogs produced elevations of systemic plasma levels of insulin, glucagon, and pancreatic polypeptide (PP). In the dog, infusions of GRP produced dose-dependent decreases in plasma glucose levels, whereas, in the sheep, dose-dependent increases in plasma glucose levels occurred. Glucose turnover studies demonstrated that infusions of GRP produce prompt increases in the rate of appearance of glucose in sheep, but previous studies demonstrated a transient decrease in the rate of appearance of glucose in dogs, suggesting that sheep and dogs differ in hepatic responses to the elevated levels of insulin and glucagon. GRP was a potent PP secretagogue in the sheep, whereas, in contrast to results in the dog, infusions of GRP did not result in elevations of plasma levels of gastrin in sheep. GRP has multiple complex stimulatory effects on the endocrine pancreas, and there exist species-dependent differences in responses, which affect the potency and spectrum of the hormone-releasing activity of GRP. Further studies are required to determine the precise anatomical relation of GRP-containing nerve fibers to islet cells and to elucidate the pathways by which GRP activates endocrine pancreatic hormone release.
Collapse
Affiliation(s)
- T J McDonald
- Department of Medicine, University of Western Ontario, London, Canada
| | | | | | | |
Collapse
|
13
|
Scarpignato C, Gioffré M, Gulino FM, Micali B. Different effects of bombesin on glucose- and tolbutamide-induced insulin release in man. Br J Pharmacol 1988; 94:1023-8. [PMID: 3061541 PMCID: PMC1854094 DOI: 10.1111/j.1476-5381.1988.tb11617.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
1. The effect of bombesin, a neurogastrointestinal peptide, on basal and stimulated insulin release was studied in man. 2. Two different stimuli were used, hyperglycaemic (20 g glucose) and hypoglycaemic (1 g tolbutamide). They were injected intravenously to two groups of male healthy volunteers during saline or bombesin (5 ng kg-1 min-1 for 60 min) infusion. 3. The peptide had no significant effect on basal levels of glucose and insulin. However, the insulin response to intravenous glucose was strongly potentiated by bombesin, the integrated insulin response being 2.23 +/- 0.59 mu ml-1 . 90 min and 0.98 +/- 0.19 mu ml-1 . 90 min during infusion of bombesin and saline, respectively (P less than 0.05). The behaviour of plasma glucose was not significantly modified by the peptide. Indeed, the glucose disappearance rate (K of Conard, mg min 10(-2)) changed from 2.5 +/- 0.3 during saline to 2.4 +/- 0.4 during bombesin infusion. 4. When the hypoglycaemic stimulus (i.e. tolbutamide) was used, no effect of the peptide on insulin release could be detected. Here again, the drop in plasma glucose (expressed as Marigo's coefficient) was not affected by the peptide, with a value of 92.8 +/- 12.6 and 84.0 +/- 10.9 during bombesin and saline administration. 5. These data therefore show that, at normal or low blood glucose levels, the dose of bombesin used is unable to modify insulin release and suggest that this peptide might be regarded as a glucose-dependent insulinotropic peptide.
Collapse
Affiliation(s)
- C Scarpignato
- Institute of Pharmacology, School of Medicine and Dentistry, University of Parma, Italy
| | | | | | | |
Collapse
|
14
|
Swope SL, Schonbrunn A. Characterization of ligand binding and processing by bombesin receptors in an insulin-secreting cell line. Biochem J 1987; 247:731-8. [PMID: 2827637 PMCID: PMC1148473 DOI: 10.1042/bj2470731] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Bombesin is a tetradecapeptide which stimulates insulin secretion in vivo by isolated islets and by HIT-T15 cells, a clonal line of hamster pancreatic-islet cells. In the present study we have used [125I-Tyr4]bombesin to characterize bombesin receptors in HIT-T15 cells. [125I-Tyr4]Bombesin binding was time- and temperature-dependent: maximum binding occurred after 45 min, 90 min and 10 h at 37, 22 and 4 degrees C respectively. Thereafter, cell-associated radioactivity declined at 37 degrees C and 22 degrees C but not at 4 degrees C. Scatchard analysis of [125I-Tyr4]bombesin binding measured at 4 degrees C showed that HIT-T15 cells contain a single class of binding sites (approximately equal to 85000/cell) with an apparent Kd of 0.9 +/- 0.11 nM. Structurally unrelated neuropeptides did not compete for [125I-Tyr4]bombesin binding. However, the relative potencies of bombesin and four bombesin analogues in inhibiting the binding of [125I-Tyr4]bombesin correlated with their ability to stimulate insulin release. Receptor-mediated processing of [125I-Tyr4]bombesin was examined by using an acid wash (0.2 M-acetic acid/0.5 M-NaCl, pH 2.5) to dissociate surface-bound peptide from the cells. Following [125I-Tyr4]bombesin binding at 4 degrees C, more than 85% of the cell-associated radioactivity could be released by acid. When the temperature was then increased to 37 degrees C, the bound radioactivity was rapidly (t1/2 less than 3 min) converted into an acid-resistant state. These results indicate that receptor-bound [125I-Tyr4]bombesin is internalized in a temperature-dependent manner. In fact, the entire ligand-receptor complex appeared to be internalized, since pretreatment of cells with 100 nM-bombesin for 90 min at 37 degrees C decreased the subsequent binding of [125I-Tyr4]bombesin by 90%. The chemical nature of the cell-associated radioactivity was determined by reverse-phase chromatography of the material extracted from cells after a 30 min binding incubation at 37 degrees C. Although 70% of the saturably bound radioactivity was co-eluted with intact [125I-Tyr4]bombesin 90% of the radioactivity subsequently dissociated from cells chromatographed as free iodide. At least some of the degradation of receptor-bound [125I-Tyr4]bombesin appeared to occur in lysosomes, since chloroquine increased the cellular accumulation of [125I-Tyr4]bombesin at 37 degrees C and slowed the release of radioactivity.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- S L Swope
- Department of Pharmacology, Harvard Medical School, Boston, MA
| | | |
Collapse
|
15
|
Schnuerer EM, McDonald TJ, Dupre J. Inhibition of insulin release by galanin and gastrin-releasing peptide in the anaesthetized rat. REGULATORY PEPTIDES 1987; 18:307-20. [PMID: 2445005 DOI: 10.1016/0167-0115(87)90188-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The present study was designed to determine the effects of intravenously administered galanin or gastrin-releasing peptide (GRP) on glucose- and/or glucose-dependent insulinotropic peptide (GIP)-stimulated insulin release in the anaesthetized rat. Galanin inhibited glucose-stimulated insulin responses in a dose-related manner. Galanin also inhibited insulin release in response to glucose administered with GIP; this effect was due largely to inhibition of the glucose-stimulated component since galanin did not inhibit GIP-stimulated insulin release. Galanin also inhibited insulin responses to ingestion of a mixed meal. GRP inhibited glucose-stimulated insulin responses, and the insulin responses to glucose plus GIP; unlike galanin, GRP inhibited both glucose- and GIP-stimulated insulin release. GRP also inhibited insulin release following ingestion of a mixed meal. The results suggest a possible modulatory role for these neuropeptides in regulation of insulin secretion.
Collapse
Affiliation(s)
- E M Schnuerer
- Department of Physiology, University of Western Ontario, London, Canada
| | | | | |
Collapse
|
16
|
Knuhtsen S, Holst JJ, Schwartz TW, Jensen SL, Nielsen OV. The effect of gastrin-releasing peptide on the endocrine pancreas. REGULATORY PEPTIDES 1987; 17:269-76. [PMID: 2885899 DOI: 10.1016/0167-0115(87)90284-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The 27-amino acid peptide gastrin releasing peptide (GRP-(1-27] was infused at 4 dose levels (0.01, 0.1, 1.0, and 10 nM) into the arterial line of the isolated perfused porcine pancreas. Infusions were performed at 3 different perfusate glucose levels (3.5, 5.0, and 8.0 mM) and at two levels of amino acids (5 and 15 mM). GRP-(1-27) stimulated insulin and pancreatic polypeptide secretion and inhibited somatostatin secretion in a dose-dependent manner. Glucagon secretion was unaffected by infusion of GRP under all circumstances. The effect of GRP-(1-27) on insulin secretion was enhanced with increasing perfusate glucose levels, whereas the effects upon somatostatin and pancreatic polypeptide secretion were independent of perfusate glucose levels. The responses to GRP were unaffected by elevation of the concentration of amino acids in the perfusate. The effects of GRP were unaffected by atropine at 10(-6) M. The localization of GRP within the porcine pancreas, its release during electrical stimulation of the vagus nerve, and its potent effects upon pancreatic endocrine secretion make it conceivable that the peptide participates in parasympathetic regulation of pancreatic endocrine secretion.
Collapse
|
17
|
Abstract
The effect of bombesin on insulin and gastrin response to a standard labelled meal was studied in eight healthy male volunteers. The gastric emptying of solids was simultaneously evaluated. During intravenous infusion of the peptide (5 ng/kg/min) the insulin release after eating was greatly reduced whereas food stimulated gastrin release was significantly enhanced. Both effects of bombesin are likely to be connected with the marked inhibition of gastric emptying induced by the peptide.
Collapse
|
18
|
Abstract
A unique subset of interneurons which are rich in immunoreactive somatostatin (IRS) exists in the cerebral cortex. The regulation of IRS secretion by these cells is reviewed. Acetylcholine, glutamic acid and several neuropeptides including VIP, CCK, and metenkephalin have been identified as IRS secretagogues. The types of molecules which stimulate IRS release, the electrophysiologic effects of somatostatin, and the recognition of abnormal IRS levels in human CNS diseases were all used to formulate a working model of the role of the somatostatinergic cell in ongoing cerebral cortical function.
Collapse
|
19
|
Swope SL, Schonbrunn A. Bombesin stimulates insulin secretion by a pancreatic islet cell line. Proc Natl Acad Sci U S A 1984; 81:1822-6. [PMID: 6143320 PMCID: PMC345013 DOI: 10.1073/pnas.81.6.1822] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
The amphibian tetradecapeptide, bombesin (BBS) has been shown to stimulate insulin secretion both in vivo and by pancreatic islet cells in vitro. To determine whether BBS can act directly on pancreatic beta cells, we examined its effects on insulin secretion by HIT-T15 cells (HIT cells), a clonal islet cell line. Addition of 100 nM BBS to HIT cells stimulated insulin release 25-fold within 30 sec. The rapid stimulatory effect of BBS on insulin release was short-lived: the secretory rate returned to basal levels after 90 min of BBS treatment. The decrease in the rate of insulin release in the continued presence of BBS was due not to depletion of intracellular insulin stores but to specific desensitization to this peptide. Stimulation of insulin secretion by BBS was dose dependent with an ED50 value (0.51 +/- 0.15 nM) similar to the concentration of BBS-like immunoreactive material in rat plasma. Five BBS analogs, including porcine gastrin-releasing peptide, were as powerful as BBS in stimulating insulin release. The relative potencies of the analogs tested indicated that the COOH-terminal octapeptide sequence in BBS was sufficient for stimulation of release. In contrast, 14 peptides structurally unrelated to BBS did not alter insulin secretion. BBS action was synergistic with that of glucagon; insulin secretion in the presence of maximal concentrations of both peptides was greater than the additive effects of the two peptides added individually. Somatostatin inhibited BBS-stimulated release by 69 +/- 1% with an ID50 value of 3.2 +/- 0.3 nM. These results show that BBS stimulation of insulin secretion by a clonal pancreatic cell line closely parallels its effects in vivo and support the hypothesis that BBS stimulates insulin secretion by a direct effect on the pancreatic beta cell. The clonal HIT cell line provides a homogeneous cell preparation amenable for studies on the biochemical mechanisms of BBS action in the endocrine pancreas.
Collapse
|
20
|
McDonald TJ, Ghatei MA, Bloom SR, Adrian TE, Mochizuki T, Yanaihara C, Yanaihara N. Dose-response comparisons of canine plasma gastroenteropancreatic hormone responses to bombesin and the porcine gastrin-releasing peptide (GRP). REGULATORY PEPTIDES 1983; 5:125-37. [PMID: 6338565 DOI: 10.1016/0167-0115(83)90120-9] [Citation(s) in RCA: 66] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
This study compares the potencies of the porcine gastrin-releasing peptide (pGRP) and bombesin, in causing elevations of canine plasma gastroenteropancreatic (GEP) levels. In the dose range 0-600 pmol . kg-1 . h-1, infusion of both peptides resulted in obvious dose-related elevations of plasma levels of gastrin, pancreatic polypeptide, enteroglucagon, immunoreactive pancreatic glucagon, and insulin. In this dose range, no significant difference in potency between the two peptides in elevating plasma levels of the above hormones was observed. The results of this study, demonstrating equimolar potency of pGRP and bombesin, are in contrast to previous studies reporting that pGRP was less potent than bombesin in causing certain bioactivities in the rat following intracranial administration of the two peptides.
Collapse
|
21
|
Wood SM, Polak JM, Bloom SR. Neuropeptides in the control of the islets of Langerhans. ADVANCES IN METABOLIC DISORDERS 1983; 10:401-20. [PMID: 6141707 DOI: 10.1016/b978-0-12-027310-2.50021-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
22
|
Iguchi A, Sakamoto N, Burleson PD. The effects of neuropeptides on glucoregulation. ADVANCES IN METABOLIC DISORDERS 1983; 10:421-34. [PMID: 6198887 DOI: 10.1016/b978-0-12-027310-2.50022-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
23
|
Erisman MD, Linnoila RI, Hernandez O, DiAugustine RP, Lazarus LH. Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci U S A 1982; 79:2379-83. [PMID: 6285381 PMCID: PMC346197 DOI: 10.1073/pnas.79.7.2379] [Citation(s) in RCA: 123] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
The presence of immunoreactive bombesin in a human lung small-cell carcinoma grown in nude mice was established by several criteria: (i) Radioimmunoassay of tissue extracts for bombesin revealed approximately 6.5 pmol/g of tissue; (ii) bombesin was found in 12-14% of the tumor cells by immunohistochemical localization; (iii) gel filtration of small-cell carcinoma extract on Sephadex G-75 and Bio-Gel P-4 gave only a single peak of immunoreactivity, which occurred at the elution volume of bombesin; and (iv) reverse-phase HPLC of acid-solubilized extracts separated the immunoreactive material into three discrete peaks, one of which eluted with a retention time identical to that of synthetic bombesin. The presence of bombesin may represent the ectopic expression of this peptide in small-cell carcinoma, because immunoreactive bombesin was found in human fetal and neonatal lung but apparently not in adult lung tissue [Wharton, J., Polak, J. M., Bloom, S. R., Ghatei, M. A., Solcia, E., Brown, M. R. & Pearse, A. G. E. (1978) Nature (London) 273, 769-770]. The immunoreactive bombesin previously found in mammalian tissues is considerably larger than amphibian bombesin; these data substantiate the presence of a mammalian form of bombesin in a human tumor that may have a structure similar to that of the amphibian peptide.
Collapse
|
24
|
McDonald TJ, Ghatei MA, Bloom SR, Track NS, Radziuk J, Dupre J, Mutt V. A qualitative comparison of canine plasma gastroenteropancreatic hormone response to bombesin and the porcine gastrin-releasing peptide (GRP). REGULATORY PEPTIDES 1981; 2:293-304. [PMID: 7029673 DOI: 10.1016/0167-0115(81)90034-3] [Citation(s) in RCA: 75] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The effect on plasma gastroenteropancreatic hormone levels on infusing the porcine gastrin-releasing peptide and bombesin into dogs demonstrated no qualitative difference in the spectrum of activity of the two peptides. Sustained elevation in plasma immunoreactive gastrin, pancreatic polypeptide, enteroglucagon, gastric inhibitory polypeptide, pancreatic glucagon and transient elevations in plasma insulin were seen during infusions of both peptides. The similar spectrum of activities and the structural homology between the two peptides suggests that the porcine gastrin releasing peptide is the porcine counterpart of the amphibian peptide bombesin.
Collapse
|
25
|
Bauduin H, Galand N, Boeynaems JM. In vitro stimulation of prostaglandin synthesis in the rat pancreas by carbamylcholine, caerulein and secretin. PROSTAGLANDINS 1981; 22:35-51. [PMID: 6945632 DOI: 10.1016/0090-6980(81)90052-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Rat pancreas pieces spontaneously released PGE2 (2.3 ng/100 mg x 45 min) and PGF2 alpha (7.6 ng/100 mg x 45 min). This release corresponds probably to a neo-synthesis since it was abolished by indomethacin. Carbamylcholine (greater than or equal to 10 microM), caerulein (greater than or equal to 10 nM) and secretin (greater than or equal to 10 nM) stimulated the release of PGE2 and PGF2 alpha: the concentrations of stimulators required to increase PGs release were thus much higher than those which trigger enzyme secretion. Atropine specifically inhibited the cholinergic stimulation, whereas indomethacin blocked the stimulatory effects of all secretagogues. Stimulation of PGE2 and PGF2 alpha release was reduced in a Ca++-free medium, abolished by EGTA and mimicked by the ionophore A23187, underscoring the crucial role of Ca++ in the regulation of PGs synthesis by the pancreas. Neither PGE2 nor PGF2 alpha stimulated enzyme secretion in this system and indomethacin did not inhibit the secretory effect of carbamylcholine. Increased synthesis of prostaglandins in response to pancreatic secretagogues does not appear to be involved in the process of enzyme secretion.
Collapse
|
26
|
Peric-Golia L, Gardner CF, Peric-Golia M. The effect of some brain/gut peptides on plasma cholesterol levels in the rat. Peptides 1980; 1:381-2. [PMID: 6170961 DOI: 10.1016/0196-9781(80)90017-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|